Government Removes Automatic PSA Test Right for Men 50+ — Critics Warn Lives Could Be Lost

It is almost an axiom: detecting prostate cancer earlier significantly improves a patient's chance of survival. Yet the Government is preparing a change to testing guidance that will remove the automatic right for asymptomatic men aged 50 and over to request a prostate-specific antigen (PSA) blood test from their GP — leaving the decision to individual family doctors.

What Has Changed

Until now, men aged 50+ without symptoms could obtain a PSA test via their GP. New guidance issued under ministerial oversight removes that blanket entitlement and asks clinicians to exercise judgement about whether testing is appropriate. Critics say this will make the so-called "invisible killer" harder to spot.

Why Critics Are Alarmed

Prostate cancer claims around 12,000 lives each year in the UK. Approximately 20% of cases show no obvious symptoms, so relying on symptoms alone risks late diagnosis. Some men are reluctant to visit a doctor; some GPs are cautious about offering tests because of concerns over false positives and overdiagnosis. Taken together, these factors mean many cancers can be missed without easier access to testing.

Policy Choices and Priorities

Campaigners — including this newspaper — have urged targeted NHS screening to catch cancers earlier and save lives. Earlier this year ministers rejected widescale population screening. Now, by narrowing routine access to PSA tests, the Government risks prioritising short-term health-service budgets over long-term patient outcomes. Critics call this both a false economy and a moral failure.

"Making tests harder to access may save money today but could condemn thousands to incurable disease later."

During the Covid pandemic the public were repeatedly urged to "protect the NHS". The NHS exists to protect public health; policy decisions should reflect patient protection first. Britain spends large sums on its health service — annual spending has roughly doubled over 17 years to about £200bn — yet cancer survival rates lag behind comparable nations and life expectancy has stalled. With an ageing population, cost pressures will grow unless strategy changes.

What Should Happen Now

Observers say ministers should reconsider the guidance and introduce targeted screening programmes to improve early detection. The decision is reported to have been taken by officials in the Department of Health without public debate; campaigners are calling on ministers to reverse it and to publish the evidence supporting the change.

Key takeaway: Changing PSA-test access shifts responsibility to GPs and, according to critics, risks missing cancers that could otherwise be detected earlier.